Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats
Investor's Business DailyGalapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
The post Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats appeared first on Inves…